Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 9 от 222

Набира участници Фаза 1

A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

Advanced relapsed or refractory ovarian cancer Advanced relapsed or refractory endometrial cancer Advanced relapsed or refractory germ cell tumours

Trial status: Authorised

Начало: 20.04.2026 Възраст: от 18 г.

Belgium, France, Germany Boehringer Ingelheim International GmbH, Boehringer Ing 2025-522913-45-00

Набира участници Фаза 4

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margar

chronic myeloid leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia

Trial status: Authorised

Начало: 20.04.2026 Възраст: 18–64 г.

Romania Sun Pharmaceutical Industries Limited 2025-524311-37-00

Набира участници Фаза 4

Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.

No medical condition.

Trial status: Authorised

Начало: 20.04.2026 Възраст: 18–64 г.

Portugal Institut De Recherches Internationales Servier IRIS 2026-525823-26-00

Набира участници Фаза 4

CoCo-PCOS - Comprehensive Health Effects of Combined Contraceptives: a 6-month randomized, controlled, open-label trial of E4+DRSP, EE20µg+DRSP, and DRSP-only in women with PCOS

Contraception

Trial status: Authorised 6-month use of study preparation, endpoint visit

Начало: 20.04.2026 Възраст: 18–64 г.

Finland Pohjois-Pohjanmaan hyvinvointialue, University Of Oulu 2025-523358-15-00

Набира участници Фаза 4

Impact of treatment with TransCon PTH on Quality of Life, cognitive function, brain structure, and cerebral capillary bloodflow in patients with hypoparathyroidism

Hypoparathyroidism

Trial status: Authorised Correlation between cognitive impairment measured by neuropsychological assessment and capillary transit time heterogeneity, cortical blood volume and hemodynamic parameters., Status of cognitive function in PTH treated compared to conventional treated controls, Difference in groups in size of structures in the brain. Difference in microvascular hemodynamic between PTH- and conventionally treated patients with chronic HypoPT

Начало: 20.04.2026 Възраст: от 18 г.

Denmark Region Midtjylland 2025-523930-14-00

Набира участници

Dietary Peanuts and Nutrition-Related Outcomes

Dietary Change Obesity & Overweight Food Acceptance

This study will look at how eating peanuts every day might affect participants weight, how healthy their diet is, and how they feel when eating. Investigators want to see if adding peanuts to meals for 12 weeks helps participants feel fuller, have more energy, and improve body composition. The study will include adults who have been taking GLP-1 medicines like semaglutide or tirzepatide for at least three months. Investigators also want to see if eating peanuts improves overall diet quality and health markers like tiredness and certain levels in blood.

Начало: 20.04.2026 Край: 01.12.2027 Възраст: 18–80 г.

United States Ian J. Neeland, MD NCT07244458

Набира участници

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Medulloblastoma

The study is being done to learn more about the long-term health and well-being of participants treated for medulloblastoma. The study is to decide which evaluations focusing on therapy-related lasting effects (or toxicities) should be considered. Medulloblastoma outcomes have improved with contemporary therapies including modern neurosurgical techniques and risk-adapted radiotherapy and chemotherapy regimens. However, survivors remain at risk for long-term health problems such as neurocognitive deficits, hearing loss, impaired cardiorespiratory fitness and physical performance, cardiac and neuroendocrine dysfunction, musculoskeletal conditions, and infertility.

Начало: 20.04.2026 Край: 01.10.2031

United States St. Jude Children's Research Hospital NCT07085325

Набира участници

Screening for Biomarkers of Osteonecrosis of the Femoral Head

Osteonecrosis of the Femoral Head

Osteonecrosis of the femoral head (ONFH) presents a rapidly progressive natural disease course. Femoral head collapse may occur within two years, ultimately necessitating total hip arthroplasty and imposing a heavy medical and economic burden on patients. Early intervention can significantly improve the long-term prognosis of ONFH. However, due to the lack of validated biomarkers for early diagnosis, the early diagnostic rate remains low, with a primary diagnostic rate of merely 68.43% at the first visit, accompanied by a high rate of misdiagnosis. This project intends to collect blood samples from patients diagnosed with ONFH and suspected cases in the orthopedic outpatient department of a tertiary Grade A hospital. Diagnostic and differential diagnostic tests will be adopted to evaluate the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with excellent diagnostic validity and reliability. Meanwhile, clinical data will be collected to identify independent risk factors, and a multi-dimensional integrated diagnostic model will be further established. The research findings are expected to provide solid data support, theoretical basis and technical reserves for the early prevention, early diagnosis and individualized intervention of osteonecrosis of the femoral head.

Начало: 20.04.2026 Край: 30.05.2027 Възраст: 18–70 г.

China The First Affiliated Hospital of Xinxiang Medical Colle NCT07545616

Набира участници

Caregiver Burden in Caregivers of Patients With Multiple Sclerosis

Multiple Sclerosis

Individuals aged 18-80 years who have been clinically diagnosed with multiple sclerosis and their caregivers will be included in the study. Demographic data of the patients, including age, height, weight, and comorbidities, will be recorded. Disease-specific characteristics such as disease duration, presence of incontinence, ambulation status, and presence and severity of pain will be assessed. Functional status of the patients will be evaluated using the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Impact Scale (MSIS). Symptoms related to depression and anxiety in patients will be assessed using the Hospital Anxiety and Depression Scale (HADS). Subsequently, caregivers of the patients will be evaluated. The severity of insomnia will be assessed using the Insomnia Severity Index (ISI). Symptoms related to anxiety and depression will be evaluated using the Hospital Anxiety and Depression Scale (HADS). Caregiver burden will be assessed using the Zarit Caregiver Burden Scale.

Начало: 20.04.2026 Край: 20.05.2026 Възраст: 18–80 г.

Turkey (Türkiye) Istanbul Physical Medicine Rehabilitation Training and NCT07549048

Набира участници

Screening for Biomarkers of Osteoarthritis

Osteoarthritis (OA)

Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide, which causes pain, loss of joint function and declined quality of life, and ranks as the leading cause of disability among individuals aged over 60 years. In China, the number of patients with osteoarthritis is projected to exceed 200 million by 2044, resulting in a continuously growing demand for medical resources and escalating economic burden.Nevertheless, the lack of effective biomarkers for early diagnosis leads to advanced disease conditions at the time of initial medical consultation and delayed treatment. This project intends to collect blood samples from OA patients and suspected patients in the orthopedic outpatient department of a tertiary hospital. Diagnostic and differential diagnostic tests will be adopted to verify the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with favorable validity and reliability. The research findings are expected to provide data support and theoretical basis for the early prevention, early diagnosis and individualized intervention of osteoarthritis.

Начало: 20.04.2026 Край: 30.12.2026 Възраст: 40–70 г.

China The First Affiliated Hospital of Xinxiang Medical Colle NCT07544823

Набира участници

Effects of Menstrual Cycle on Optic Nerve Sheath Diameter in Patients Undergoing Laparoscopic Gynecologic Surgery

Menstrual Cycle Optic Nerve Sheath Diameter Postoperative Nausea and Vomiting

This observational study aims to evaluate the effect of menstrual cycle phase on optic nerve sheath diameter (ONSD) in women undergoing elective laparoscopic gynecologic surgery. Patients will be grouped according to menstrual cycle phase as follicular or luteal. ONSD measurements will be performed perioperatively, and postoperative nausea and vomiting as well as postoperative cognitive function will also be assessed. The study is designed to investigate whether hormonal variations during the menstrual cycle are associated with differences in intracranial pressure reflected by ONSD measurements and postoperative outcomes

Начало: 20.04.2026 Край: 05.04.2027 Възраст: 18–45 г.

Turkey (Türkiye) Konya City Hospital NCT07539831

Набира участници

BiFeS vs. iPACK in Postoperative Knee Arthroplasty Analgesia

Arthroplasty, Replacement, Knee Pain, Postoperative Anesthesia, Regional

The Biceps Femoris Short Head (BiFeS) block is a new fascial plane block technique targeting the sensory innervation of the posterolateral capsule of the knee while preserving motor function. The aim of this study is to evaluate the postoperative analgesic efficacy of the BiFeS block combined with the adductor canal block (ACB) in patients undergoing total knee arthroplasty, compared to ACB + iPACK block. The study is planned as a prospective, randomized, double-blind, parallel two-group trial. Patients will be randomized in a 1:1 ratio to receive ACB + iPACK (Group A) or ACB + BiFeS (Group B). Postoperative pain scores (VAS), opioid consumption, early mobilization, and quality of recovery (QoR-15) outcomes will be compared.

Начало: 20.04.2026 Край: 01.06.2027 Възраст: 18–80 г.

Turkey (Türkiye) Amasya University NCT07360392

Набира участници Фаза 2

DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

Stroke

Spontaneous intracerebral haemorrhage (ICH) is a life-threatening condition, still devoided of specific treatment. Peri-haematomal oedema (PHO) develops in the ensuing days after ICH onset and worsens functional outcome. Hence, PHO is a promising therapeutic target but until now there is no specific treatment for PHO. The occurrence and growth of PHO is mainly mediated by inflammation. We hypothesize that a modulation of inflammation is effective in reducing PHO growth, therefore improving the functional outcome of ICH patients. From animal studies to human post-mortem studies, our team has demonstrated a key role for erythroid-related nuclear factor 2 (Nrf2) in PHO. Indeed, this transcription factor promotes the protective effect of inflammation: Nrf2 activation enhances antioxidant defenses and increases rates of blood resorption. Therefore, Nrf2 emerges as a promising and innovative therapeutic target. Taking into account the prolonged time interval between de novo drug discovery and use in clinical practice, drug repurposing is an interesting option for the unmet clinical need of reducing PHO. We chose Diroximel Fumarate (DRF) which is a safe and effective Nrf2 activator widely used in multiple sclerosis (dimethyl fumarate is on the market since 2013, and DRF since 2019) to modulate inflammation and to establish the efficacy of Nrf2 activation in reducing PHO growth and, ultimately, in improving the functional prognosis after ICH.

Начало: 20.04.2026 Край: 01.04.2029 Възраст: от 18 г.

France University Hospital, Lille NCT07275515

Набира участници

Sodium vs Potassium Education to Improve Vascular Health

Healthy

The goal of this clinical trial is to determine if a self-selected high potassium diet is easier to achieve and more effective at improving vascular health than a low sodium diet in generally healthy young adults who typically consume more than the recommended amount of sodium. The main questions it aims to answer are: 1. Is it easier for young adults to increase their potassium intake, rather than reduce their sodium intake? 2. Is a self-selected high potassium diet better at improving vascular health compared to a self-selected low sodium diet? Researchers will compare the effectiveness of an education-based intervention centered only on increasing dietary potassium intake against an education-based intervention centered only on reducing dietary sodium intake. Participants will be randomly assigned to receive comprehensive dietary education on adopting either a high-potassium diet or a low-sodium diet. Education will be delivered in four weekly one-on-one sessions. Following the four-week education period, participants will be encouraged to change their diet based on what they have learned. Measures of dietary compliance (urine samples and diet records) and cardiovascular health (blood pressure, endothelial function) will be assessed at two, four, and six months post-education.

Начало: 20.04.2026 Край: 30.09.2027 Възраст: 18–45 г.

United States Florida State University NCT07221448

Набира участници Фаза 3

KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial

Adult patients admitted to the ICU and receiving unplanned invasive mechanical ventilation

Trial status: Authorised The number of days alive free of encephalopathy (coma or delirium measured on the CAM-ICU) during 14 days after randomization, The number of days spent alive without invasive mechanical ventilation (ventilation-free days) at 60 days;, The number of days spent alive without infusion norepinephrine or inotropes infusion during ICU stay (vasopressors-free days) at 60 days;, Mortality, defined by the prevalence of all-cause deaths at 60 and 90 days;, Toxicité rénale, définie par la proportion de patients atteignant un stade KDIGO ≥2 à 60 jours ;, Liver toxicity, defined by the highest bilirubin and phosphatase alkaline level during the first 60 days;, Quantification of opioid and sedative consumption during the treatment period, in each arm during the first 14 days., Mean daily pain (BPS) and sedation (RASS) scores, in each arm during the first 14 days, Cumulative incidence of hallucination events during 14 days after randomization, Presence of anxiety and depression, defined by a score ≥11 on the anxiety and depression components of the Hospital Anxiety and Depression scale, respectively at 90 days; (tertiary outcome), Acute posttraumatic stressdisorder (PTSD)-related (measured on the ICU memory tool) at 90 days. (tertiary outcome) The primary endpoint will be the number of days patients are alive and spent at home at 60 days after drug or placebo initiation. This endpoint will be collected by an independent research assistant, blinded to randomization groups and not involved in data monitoring onsite.

Начало: 20.04.2026 Възраст: от 18 г.

France Assistance Publique Hopitaux De Paris 2025-523149-80-00

Набира участници Фаза 3

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

treatment-naive Chronic Lymphocytic Leukemia

Trial status: Authorised • uMRD4 rate defined as the proportion of patients that achieved uMRD4 measured in both PB and BMA at the PTFU1 Visit based on next-generation sequencing (NGS [clonoSEQ]), • PFS as determined by IRC in high-risk patients that have unmutated IGHV and/or TP53 aberrations (del(17p) present and/or TP53 mutated), • OS, defined as time from the date of randomization to the date of death due to any cause, • ORR defined as the proportion of patients with a CR, CRi, nodular partial response (nPR), or partial response (PR) per the IRC assessment, • uMRD5 rate defined as the proportion of patients that achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS (clonoSEQ), • Adverse events (AEs), adverse events of clinical interest (AECIs), serious adverse events (SAEs), changes from baseline in clinical laboratory tests, physical examinations, and vital signs, • PFS determined by investigator assessment, • Overall CRR determined by IRC and by investigator assessment., • ORR determined by investigator assessment, • Duration of response (DOR; determined by both IRC and investigator assessment) defined as the time from first qualifying response (CR, CRi, nPR, or PR) until disease progression or death, • Time to next treatment (TTNT) defined as the time from randomization to the start of next treatment for CLL, • Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden, and physical condition/fatigue measured by European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 • PFS, defined as time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

Начало: 20.04.2026 Възраст: от 18 г.

Czech Republic, France, Germany +3 BeOne Medicines I GmbH 2025-524366-21-00

Набира участници Фаза 2

A randomized phase II study comparing the safety and efficacy of mifamurtide and standard therapy containing sorafenib in pediatric and young adult patients with high-risk osteosarcoma

Relapsed/refractory osteosarcoma High-grade osteosarcoma

Trial status: Authorised OS (Overall Survival) – Overall survival will be measured from randomization to death from any cause; for patients alive at the end of follow-up, data will be censored at the date of last confirmed contact., PFS (Progression-Free Survival) – Progression-free survival will be measured from randomization to the date of disease progression or death, whichever occurs first., ORR (Overall Response Rate) – Response rate, defined as the percentage of patients with the best documented complete response (CR) or partial response (PR), assessed according to RECIST v1.1 at the time points specified in the imaging schedule., Evaluation of the safety of mifamurtide in patients with osteosarcoma. Safety will be assessed based on the number of serious adverse events (SAEs), the number of adverse events (AEs), a physical examination with analysis of recorded vital signs and laboratory abnormalities according to NCI CTCAE v5.0, from the start of treatment to the end of safety follow-up according to the study schedule. EFS (Event-Free Survival) – the time from randomization to the first event, i.e., death, disease progression, or disease relapse, whichever occurs first. Assessment will be conducted from the date of randomization to the date of the event or to the date of the last available assessment.

Начало: 20.04.2026 Възраст: 18–64 г.

Poland Instytut Matki I Dziecka 2026-525223-24-00

Набира участници Фаза 3

A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with Non-permanent Atrial Fibrillation

Non-permanent Atrial Fibrillation

Trial status: Authorised Secondary Efficacy: • Change in percent AFSS during final month of treatment compared to baseline for multiple doses of budiodarone. • PGI-C during the final month of treatment. • Percent change in AFB during final month of treatment compared to baseline. Safety: • Incidence of TEAE and treatment-emergent serious adverse events (TESAE). • Incidence of AESI • Mortality and Clinical Morbidity Events: o Death o Resuscitated sudden cardiac death (SCD) including appropriate implanted cardiac defibrillator (ICD) discharge o Cardiovascular hospitalization o Stroke or another thromboembolic event • Physical Exam assessments and abnormalities. • Vital sign assessments and abnormalities. • Clinical laboratory assessment and abnormalities. o Thyroid functio, Primary Efficacy: • Proportion of participants that have no LEAF (uninterrupted episode of AF that is 5 hours or longer in duration or cumulative duration of AF in any rolling 24-hour period that is greater than 5 hours) in the final month of treatment., Exploratory Endpoint: • The proportion of participants with no LEAF episodes lasting one hour or longer in the final month of budiodarone treatment

Начало: 20.04.2026 Възраст: от 18 г.

Poland Xyra LLC 2025-523860-19-00

Набира участници Фаза 2

Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases

colon carcinoma metastases

Trial status: Authorised Establishment of Efficacy (main study part 3): • Liver volume on POD1 and POD7 and increase in liver volume at POD7 vs. POD1 (absolute change from POD1 CT) Incidence, severity, and relatedness of AEs/SAEs, Changes from baseline in vital signs and physical examination findings, Changes from baseline in clinical laboratory parameters (hematology,blood, glucose) at prespecified time points, Plasma PK of HRX215 (Cmax, Tmax, AUC etc.); comparison with Phase 1 healthy-subject PK data

Начало: 20.04.2026 Възраст: от 18 г.

France, Germany HepaRegeniX GmbH 2025-523630-59-00

Набира участници Фаза 1

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia Acute Myeloid Leukemia

Trial status: Authorised Complete Remission (CR), Composite Complete Remission (CR + CRi), Composite Complete Remission (CR + CRh), Duration of Complete Remission (DOCR), Duration of Composite Complete Remission (CR + CRi), Duration of Composite Complete Remission (CR + CRh) Treatment-emergent adverse events (TEAEs) leading to treatment discontinuation, PK parameters for intact ADC and payload (FGN849), including Cmax, AUC, and Tmax

Начало: 20.04.2026

Belgium, Czech Republic, France +1 AbbVie Deutschland GmbH & Co. KG 2024-520125-36-00

1 … 7 8 9 10 11 … 222